JMP Securities Downgrades Cerus (CERS) to Market Underperform
More News related to CERS
- Trading Review for Cerus Corp. Issued by Beacon Equity
- Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance for Proposed INTERCEPT Blood System Phase III Trial Design
- Cerus (CERS) Halted As FDA To Review Proposed Phase III Clinical Trial Design for the INTERCEPT Blood System
- Cerus Corporation Stock Trading Halted; FDA Blood Products Advisory Committee to Review and Discuss Proposed Phase III Clinical Trial Design for the INTERCEPT Blood System
- Cerus (CERS) Misses Q3 EPS by 4c
More News related to Downgrades
- RBC Capital Downgrades Church & Dwight (CHD) from Top Pick to Outperform
- JMP Securities Downgrades NuVasive (NUVA) to Market Perform
- Brean Murray Downgrades NuVasive (NUVA) to Hold; Reimbursement Issues Struck a Nerve
- Merriman Curhan Ford Downgrades Netflix (NFLX) to Neutral; Risk Lies More With Initial 1Q Guidance
JMP Securities downgrades Cerus (Nasdaq: CERS) from Market Perform to Market Underperform.
Cerus Corporation, a biomedical products company, engages in the development and commercialization of the INTERCEPT Blood System.
Related Categories
DowngradesStocks Mentioned
+0.12Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
